Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy

Abstract

Basic fibroblast growth factor (bFGF)-loaded liposome (bFGF-lip) combined with ultrasound-targeted microbubble destruction (UTMD) technique was investigated to prevent diabetic cardiomyopathy (DCM). Cardiac function and myocardial ultrastructure were assessed. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, immunohistochemistry staining, and Western blot assay were used to investigate the signal pathway underlying the expression of bFGF in DCM treatment. From Mason staining and TUNEL staining, bFGF-lip + UTMD group showed significant differences from the diabetes group and other groups treated with bFGF or bFGF-lip. The diabetes group showed similar results (myocardial capillary density, collagen volume fraction, and cardiac myocyte apoptosis index) to other bFGF treatment groups. Indexes from transthoracic echocardiography and hemodynamic evaluation also proved the same conclusion. These results confirmed that the abnormalities including diastolic dysfunctions, myocardial fibrosis, and metabolic disturbances could be suppressed by the different extents of twice-weekly bFGF treatments for 12 consecutive weeks (free bFGF or bFGF-lip +/− UTMD), with the strongest improvements observed in the bFGF-lip + UTMD group. The group combining bFGF-lip with UTMD demonstrated the highest level of bFGF expression among all the groups. The bFGF activated the PI3K/AKT signal pathway, causing the reduction of myocardial cell apoptosis and increase of microvascular density. This strategy using bFGF-lip and UTMD is a potential strategy in early intervention of DCM in diabetes.

Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: A 1H NMR-based metabolomics investigation

“…The biological activity of bFGF was validated by the company. In addition, the dose of treatment was suggested by our colleagues according to the pilot study of Zhao et al 15. Rats in the bFGF group were treated by tail-vein injection of bFGF solution at a dosage of 5 μg/kg of body weight for a 7-day continuous treatment (once daily injection at 8:00 am).…”

CoQ10-loaded liposomes combined with UTMD prevented early nephropathy of diabetic rats

“…MBs can serve as a vehicle of therapeutics to obtain specific release when exposed to low-intensity ultrasound, resulting in drug accumulation in nidus [ 25 ]. Recently, low-intensity ultrasound (US) in combination with microbubbles has been shown to improve the efficiency and tissue/organ specificity of nanoliposomes in vivo [ 26 ]. Ultrasound-mediated microbubble destruction (UTMD) is a new and promising technique applied in many fields.…”